Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2011

View Archived Issues

Novartis reflects on accomplishments of second quarter 2011

Byetta is safe and effective in Prader-Willi syndrome

Pfizer presents new MABA as clinical candidate for COPD

Diagnostic ability of PET tracer flutemetamol investigated in AD, MCI and NPH

Sanofi discloses novel protein kinase inhibitors

Takeda presents new histamine H3 receptor antagonists

Novel agents for protozoal infections claimed by Actelion

Piramal Life Sciences claims new diacylglycerol O-acyltransferase inhibitors

Katholieke Universiteit Leuven prepares novel antibacterials

Trial measures lorcaserin exposure in human cerebrospinal fluid

Femta Pharmaceuticals files IND with FDA for FM-101

Cardium Therapeutics provides update on plan to acquire Transdel

Noninvasive diabetes screening test obtains CE mark

Critical Outcome Technologies begins synthesis of AML drug candidates

FDA accepts NDA filing for Levadex

Genzyme seeks approval for mipomersen in Europe

Protalix replies to FDA complete response letter for taliglucerase alfa

AAV-mediated gene editing using ZFN technology shows promise to treat hemophilia in vivo

Alnylam completes phase I ALN-VSP trial

OncoTherapy Science's anticancer vaccine OTS-102 obtains generic name

Amarin completes remaining studies of AMR-101 required for NDA

Bionomics provides update on clinical trials of anticancer candidate BNC-105

Encouraging interim results emerge from phase III study of Paclical

EMA provides scientific advice regarding phase III trial of CPP-1X in FAP

European Commission expands RoActemra label

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...